文献速递肺栓塞与肺血管病

肺动脉高压初始治疗策略与长期生存的关联

Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

该研究基于法国肺动脉高压注册登记数据,回顾性分析1,611例特发性、遗传性或食欲抑制剂相关肺动脉高压患者的初始治疗策略与长期生存关系。结果显示初始三联治疗(含 parenteral prostacyclin)患者5年生存率91%,显著高于双联或单药治疗的61%。倾向性评分匹配后三联与双联10年生存率分别为85%和65%。

要点

  • 初始三联治疗(含 parenteral prostacyclin)与更高生存率相关。
  • 高危患者中三联治疗生存优于单药或双联,单药与双联无差异。
  • 中危患者生存随治疗药物数量增加而改善。

核心结论

  • 含 parenteral prostacyclin 的初始三联治疗与肺动脉高压患者更高生存率相关,尤其在高危年轻患者中。

研究设计与样本

  • 共纳入1,611例患者,初始单药治疗984例,双联治疗551例,三联治疗76例。

主要发现

  • 三联治疗组5年生存率91%,双联和单药治疗组均为61%(P < 0.001)。
  • 倾向性评分匹配年龄、性别和肺血管阻力后,三联与双联10年生存率分别为85%和65%。
  • 高危患者(n = 243)中三联治疗生存率高于单药或双联,单药与双联无差异。
  • 中危患者(n = 1,134)中生存率随治疗数量增加而改善。
  • 多变量Cox回归显示三联治疗与较低死亡风险独立相关(HR 0.29,95%CI 0.11-0.80,P = 0.017)。

关键数值与推荐

  • 三联治疗定义为两种口服药物联合 parenteral prostacyclin。
  • 148例接受 parenteral prostacyclin 起始治疗的患者中,三联治疗生存率高于单药或双联。

临床怎么用

  • 对肺动脉高压患者,尤其高危年轻患者,可考虑初始含 parenteral prostacyclin 的三联治疗以改善长期生存。
  • 中危患者增加治疗药物数量可能带来生存获益。

局限性

  • 回顾性研究设计可能存在选择偏倚。
  • 三联治疗组样本量较小(76例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. Methods: A retrospective analysis of incident patients with idiopathic, heritable, or anorexigen-induced PAH enrolled in the French Pulmonary Hypertension Registry (January 2006 to December 2018) was conducted. Survival was assessed according to the initial strategy: monotherapy, dual therapy, or triple-combination therapy (two oral medications and a parenteral prostacyclin). Measurements and Main Results: Among 1,611 enrolled patients, 984 were initiated on monotherapy, 551 were initiated on dual therapy, and 76 were initiated on triple therapy. The triple-combination group was younger and had fewer comorbidities but had a higher mortality risk. The survival rate was higher with the use of triple therapy (91% at 5 yr) as compared with dual therapy or monotherapy (both 61% at 5 yr) (P < 0.001). Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual therapy (10-yr survival, 85% vs. 65%). In high-risk patients (n = 243), the survival rate was higher with triple therapy than with monotherapy or dual therapy, whereas there was no difference between monotherapy and double therapy. In intermediate-risk patients (n = 1,134), survival improved with an increasing number of therapies. In multivariable Cox regression, triple therapy was independently associated with a lower risk of death (hazard ratio, 0.29; 95% confidence interval, 0.11-0.80; P = 0.017). Among the 148 patients initiated on a parenteral prostacyclin, those on triple therapy had a higher survival rate than those on monotherapy or dual therapy. Conclusions: Initial triple-combination therapy that includes parenteral prostacyclin seems to be associated with a higher survival rate in PAH, particularly in the youngest high-risk patients.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Boucly A, Savale L, Jaïs X, et al. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2021. PMID: 34185620. doi:10.1164/rccm.202009-3698OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。